Physician profile
Meredith A Donley
NPI 1639465727
$393.74
in general payments reported to CMS, 2019-2025
8 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.25 · 2023: $67.96 · 2024: $133 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.17 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142.54 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $79.49 | 2023-2024 | Tezspire, Airsupra |
| Verona Pharma, INC. | $71.73 | 2025 | Ohtuvayre |
| Eisai INC. | $28.05 | 2024 | |
| Insmed, INC. | $20.83 | 2025 | Arikayce |
| Abbvie INC. | $19.16 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.69 | 2025 | Jascayd |
| Grifols USA, LLC | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Donley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.